• Super-Enhancer Hijacking of LINC01977 Drives LUAD Progressio

  2026-04-22

  Zhang et al. (2022) reveal that super-enhancer-mediated upregulation of LINC01977 promotes malignancy in early-stage lung adenocarcinoma (LUAD) via the canonical TGF-β/SMAD3 pathway. This study offers mechanistic insights into epigenetic regulation and highlights potential molecular targets for early intervention in LUAD.

• TAI-1: Mechanistic Insights and Translational Impact of a Fi

  2026-04-22

  Discover how TAI-1, a potent Hec1 inhibitor, advances cancer research through unique mechanistic targeting and assay reliability. Explore differentiated insights on apoptotic cell death induction and translational applications in triple negative breast cancer and liver cancer models.

• Patient-Derived Gastric Cancer Assembloids Advance Drug Mode

  2026-04-21

  This study introduces a robust patient-derived gastric cancer assembloid model integrating matched tumor organoids with stromal cell subpopulations, enabling more physiologically relevant drug response and resistance studies. The innovation offers a powerful platform for dissecting tumor–stroma interactions and optimizing personalized therapies.

• Everolimus (RAD001): Scenario-Based Guidance for Cancer Assa

  2026-04-21

  This article delivers scenario-driven, evidence-based guidance for optimizing cell viability, proliferation, and cytotoxicity assays with Everolimus (RAD001) (SKU A8169). Drawing on real-world laboratory challenges, it highlights how APExBIO’s Everolimus ensures reproducibility, sensitivity, and workflow reliability for cancer research applications.

• Palbociclib (PD0332991): Cell Cycle Arrest & Cancer Assays

  2026-04-20

  Palbociclib (PD0332991) Isethionate stands out as a selective CDK4/6 inhibitor, enabling robust G0/G1 arrest and precise apoptosis assays in cancer research. With validated protocols and troubleshooting strategies, this compound empowers labs to dissect cell cycle control, tumor resistance, and optimize workflows for translational oncology.

• Palbociclib (PD0332991): Redefining Cell Cycle Control in Tr

  2026-04-20

  This thought-leadership article explores how Palbociclib (PD0332991) Isethionate, a highly selective CDK4/6 inhibitor, is revolutionizing translational cancer research. Integrating mechanistic insights, evidence-based protocol guidance, and lessons from DNA repair studies, it provides strategic direction for researchers aiming to decode tumor proliferation, resistance mechanisms, and the next generation of precision oncology.

• THZ1 and Covalent CDK7 Inhibition: Precision Tools for Trans

  2026-04-19

  This article provides a mechanistic and strategic deep dive into THZ1, a covalent CDK7 inhibitor from APExBIO, highlighting its unique selectivity, molecular mechanism, and translational potential in overcoming resistance in T-cell acute lymphoblastic leukemia (T-ALL) and broader cancer biology. It integrates critical evidence from the latest research on resistance mutations, offers actionable protocol guidance, and situates THZ1 within the evolving landscape of transcription regulation inhibitors, while advancing the conversation beyond standard product summaries.

• Bovine Insulin in Cell Culture: Applied Workflows & Insights

  2026-04-18

  Bovine insulin from APExBIO is a high-purity, proven growth supplement for cell culture, enabling robust modeling of metabolic pathways and cell proliferation. Explore actionable protocols, troubleshooting strategies, and advanced use-cases that leverage its unique properties for metabolic and cancer research.

• Bispecific Antibody Strategies for Orthopoxvirus Protection

  2026-04-17

  This study systematically characterizes monoclonal antibodies against mpox virus (MPXV) immunogens M1R and B6R, identifying neutralizing candidates and optimizing bispecific antibody formats for enhanced antiviral protection. The findings inform the development of broad-spectrum antibody therapeutics for orthopoxviruses and provide a technical foundation for future translational and diagnostic research.

• Monomethyl Auristatin E (MMAE): Microtubule Disruption, Cell

  2026-04-16

  Monomethyl auristatin E (MMAE) is a powerful antimitotic agent and a cornerstone in antibody-drug conjugate payload innovation for targeted cancer therapy. This article explores MMAE’s intersection with cancer cell plasticity, advanced assay design, and differentiation therapy—delivering unique, actionable perspectives beyond conventional workflows.

• Cyclopamine (A8340): Deep Profiling as a Hedgehog Pathway In

  2026-04-15

  Explore Cyclopamine’s role as a Hedgehog signaling inhibitor through advanced mechanistic profiling, protocol optimization, and integration with epigenetic insights. This article provides a unique, evidence-driven analysis for cancer research and developmental biology.

• Y-27632 (SKU B1293): Reliable ROCK Inhibitor for Consistent

  2026-04-14

  This article delivers a scenario-driven, evidence-based guide to using Y-27632 (SKU B1293) for cytoskeletal dynamics modulation and ROCK signaling pathway research. It addresses common laboratory challenges in cell viability and proliferation assays, highlighting how APExBIO's Y-27632 enables reproducibility and workflow optimization.

• PF-562271 HCl: Precision FAK/Pyk2 Inhibition in Cancer Resea

  2026-04-13

  Leverage the ATP-competitive FAK/Pyk2 inhibitor PF-562271 HCl for reproducible tumor growth and metastasis studies. Discover workflow enhancements, troubleshooting insights, and how recent breakthroughs guide optimal assay design.

• Disrupting c-Myc/Max: 10074-G5 as a Translational Catalyst

  2026-04-13

  This article explores the mechanistic and translational significance of 10074-G5, a small-molecule c-Myc inhibitor that disrupts the c-Myc/Max dimerization axis. Integrating recent advances in cancer research, including the MYC/TERT/NFκB pathway in esophageal adenocarcinoma, it provides strategic guidance for harnessing 10074-G5 in apoptosis assays, tumor regression studies, and next-generation therapeutic development. By leveraging evidence from both peer-reviewed literature and the APExBIO product portfolio, we position 10074-G5 not merely as a reagent but as a transformative tool in the hands of translational researchers.

• SMYD2 Inhibition Suppresses RCC Progression and Chemoresista

  2026-04-12

  This study demonstrates that inhibiting the histone methyltransferase SMYD2 impedes tumor progression and multi-drug resistance in clear cell renal cell carcinoma (ccRCC) by downregulating microRNA-125b. The findings offer valuable insight into epigenetic modulation as a means of sensitizing RCC cells to chemotherapy.

15719 records 1/1048 page Next 12345 下5页 Last page